Lantern Pharma Inc. LTRN
0.57 USD +0.04 (+6.75%)
At closeNov 6, 2026, 4:10 PM EST
0.59 +0.02 +3.89%
After hours · Nov 6, 4:10 PM ET
0.50 Day range 0.5787
0.532 52-week range 4.17
- YTD
- -81.26%
- 1 year
- -83.10%
Financial health
Altman Z-Score
-23.00 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
C+2 / 5 overall
- DCF 4
- Return on Equity 5
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -1.9×
FY 2018 5y median -2.9× FY 2025
P/S 0.0×
FY 2018 5y median 0.0× FY 2025
P/B 5.1×
FY 2018 5y median 1.2× FY 2025
P/FCF -2.1×
FY 2018 5y median -3.2× FY 2025
EV/EBITDA -6.3×
FY 2018 5y median -1.5× FY 2025
EV/Sales 0.0×
FY 2018 5y median 0.0× FY 2025
FCF Yield -47.5%
FY 2018 5y median -31.0% FY 2025
Profitability
Gross Margin 0.0%
FY 2018 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2018 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2018 5y median 0.0% FY 2025
ROE -262.0%
FY 2018 5y median -98.1% FY 2025
ROIC -21.1%
FY 2018 5y median -43.5% FY 2025
ROA -155.1%
FY 2018 5y median -81.3% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2018 FY 2025
Operating Income 19.1%
FY 2018 FY 2025
EPS (diluted) 99.9%
FY 2018 FY 2025
Free Cash Flow 12.0%
FY 2018 FY 2025
Financial Health
Current Ratio 2.4×
FY 2018 5y median 16.2× FY 2025
Quick Ratio 2.4×
FY 2018 5y median 16.2× FY 2025
Debt / Equity 12.0×
FY 2018 5y median 0.0× FY 2025
Net Debt / EBITDA -4.3×
FY 2018 5y median 0.4× FY 2025
Interest Coverage 0.0×
FY 2018 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31